233 related articles for article (PubMed ID: 26451675)
1. Warfarin time in therapeutic range and its impact on healthcare resource utilization and costs among patients with nonvalvular atrial fibrillation.
Deitelzweig S; Evans M; Hillson E; Trocio J; Bruno A; Tan W; Lingohr-Smith M; Singh P; Lin J
Curr Med Res Opin; 2016; 32(1):87-94. PubMed ID: 26451675
[TBL] [Abstract][Full Text] [Related]
2. Warfarin Management and Outcomes in Patients with Nonvalvular Atrial Fibrillation Within an Integrated Health Care System.
An J; Niu F; Zheng C; Rashid N; Mendes RA; Dills D; Vo L; Singh P; Bruno A; Lang DT; Le PT; Jazdzewski KP; Aranda G
J Manag Care Spec Pharm; 2017 Jun; 23(6):700-712. PubMed ID: 28530526
[TBL] [Abstract][Full Text] [Related]
3. Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States.
Jain R; Fu AC; Lim J; Wang C; Elder J; Sander SD; Tan H
J Manag Care Spec Pharm; 2018 Jan; 24(1):73-82. PubMed ID: 29290177
[TBL] [Abstract][Full Text] [Related]
4. Health Care Resource Utilization, Costs, and Persistence in Patients Newly Diagnosed as Having Nonvalvular Atrial Fibrillation and Newly Treated With Dabigatran versus Warfarin in the United States.
Bancroft T; Lim J; Wang C; Sander SD; Swindle JP
Clin Ther; 2016 Mar; 38(3):545-56.e1-6. PubMed ID: 26856927
[TBL] [Abstract][Full Text] [Related]
5. Suboptimal Anticoagulant Management in Japanese Patients with Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention.
Hirano T; Kaneko H; Mishina S; Wang F; Morita S
J Stroke Cerebrovasc Dis; 2017 Oct; 26(10):2102-2110. PubMed ID: 28532651
[TBL] [Abstract][Full Text] [Related]
6. Outcomes associated with warfarin time in therapeutic range among US veterans with nonvalvular atrial fibrillation.
Liu S; Li X; Shi Q; Hamilton M; Friend K; Zhao Y; Horblyuk R; Hede S; Shi L
Curr Med Res Opin; 2018 Mar; 34(3):415-421. PubMed ID: 28945114
[TBL] [Abstract][Full Text] [Related]
7. Impact of Warfarin Persistence on Health-Care Utilization and Costs Among Patients With Atrial Fibrillation Managed in Anticoagulation Clinics in the United States.
Deitelzweig SB; Evans M; Trocio J; Gupta K; Lingohr-Smith M; Menges B; Lin J
Clin Appl Thromb Hemost; 2018 Mar; 24(2):364-371. PubMed ID: 28135822
[TBL] [Abstract][Full Text] [Related]
8. Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting.
Lin J; Trocio J; Gupta K; Mardekian J; Lingohr-Smith M; Menges B; You M; Nadkarni A
J Med Econ; 2017 Sep; 20(9):952-961. PubMed ID: 28604139
[TBL] [Abstract][Full Text] [Related]
9. Out-of-range international normalized ratio values and healthcare cost among new warfarin patients with non-valvular atrial fibrillation.
Nelson WW; Wang L; Baser O; Damaraju CV; Schein JR
J Med Econ; 2015 May; 18(5):333-40. PubMed ID: 25549062
[TBL] [Abstract][Full Text] [Related]
10. Healthcare resource utilization and costs among nonvalvular atrial fibrillation patients initiating rivaroxaban or warfarin in skilled nursing facilities: a retrospective cohort study.
Mittal VS; Wu B; Song J; Milentijevic D; Ashton V; Mahajan D
Curr Med Res Opin; 2020 Apr; 36(4):529-536. PubMed ID: 31858841
[No Abstract] [Full Text] [Related]
11. International normalized ratio stability in warfarin-experienced patients with nonvalvular atrial fibrillation.
Nelson WW; Desai S; Damaraju CV; Lu L; Fields LE; Wildgoose P; Schein JR
Am J Cardiovasc Drugs; 2015 Jun; 15(3):205-11. PubMed ID: 25944648
[TBL] [Abstract][Full Text] [Related]
12. Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users.
Laliberté F; Cloutier M; Crivera C; Nelson WW; Olson WH; Schein J; Vanderpoel J; Germain G; Lefebvre P
Clin Ther; 2015 Mar; 37(3):554-62. PubMed ID: 25749196
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Healthcare Resource Utilization and Costs between Rivaroxaban and Warfarin for Nonvalvular Atrial Fibrillation in a Skilled Nursing Facility Setting.
Mahajan D; Wu B; Song J; Milentijevic D; Ashton V; Mittal VS
Drugs Aging; 2020 Apr; 37(4):281-289. PubMed ID: 32147804
[TBL] [Abstract][Full Text] [Related]
14. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
[TBL] [Abstract][Full Text] [Related]
15. Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users.
Laliberté F; Cloutier M; Crivera C; Nelson WW; Olson WH; Schein J; Vanderpoel J; Germain G; Lefebvre P
Adv Ther; 2015 Mar; 32(3):216-27. PubMed ID: 25784509
[TBL] [Abstract][Full Text] [Related]
16. Health care burden of dyspepsia among nonvalvular atrial fibrillation patients.
Kim MH; Bell KF; Makenbaeva D; Wiederkehr D; Lin J; Graham J
J Manag Care Spec Pharm; 2014 Apr; 20(4):391-9. PubMed ID: 24684644
[TBL] [Abstract][Full Text] [Related]
17. Warfarin treatment among Finnish patients with atrial fibrillation: retrospective registry study based on primary healthcare data.
Hallinen T; Soini EJ; Asseburg C; Kuosmanen P; Laakkonen A
BMJ Open; 2014 Feb; 4(2):e004071. PubMed ID: 24578536
[TBL] [Abstract][Full Text] [Related]
18. Healthcare utilization and costs for patients initiating Dabigatran or Warfarin.
Reynolds SL; Ghate SR; Sheer R; Gandhi PK; Moretz C; Wang C; Sander S; Costantino ME; Annavarapu S; Andrews G
Health Qual Life Outcomes; 2017 Jun; 15(1):128. PubMed ID: 28637460
[TBL] [Abstract][Full Text] [Related]
19. International normalized ratio stabilization in newly initiated warfarin patients with nonvalvular atrial fibrillation.
Nelson WW; Desai S; Damaraju CV; Lu L; Fields LE; Wildgoose P; Schein JR
Curr Med Res Opin; 2014 Dec; 30(12):2437-42. PubMed ID: 25170587
[TBL] [Abstract][Full Text] [Related]
20. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.
Singer DE; Hellkamp AS; Piccini JP; Mahaffey KW; Lokhnygina Y; Pan G; Halperin JL; Becker RC; Breithardt G; Hankey GJ; Hacke W; Nessel CC; Patel MR; Califf RM; Fox KA;
J Am Heart Assoc; 2013 Feb; 2(1):e000067. PubMed ID: 23525418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
